PLUS1
10.97
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immuron Ltd | IMRN | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 10.97 | 0.00 | 0.00 | 0.00 | 10.97 | 07:16:34 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 10.76 | 11.00 | 0.24 | 2.18% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume |
|---|---|---|---|---|
| 4 | 365 | 10.97 | 4,004 | 3,614,459 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:00:04 | formt | 344 | 10.97 | USD |
Immuron Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 60.60M | 5.52M | 5.52M | - | - | -0.90 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | 0.00% | - | - |
News Immuron
| Date | Time | Source | Heading |
|---|---|---|---|
| 7/29/2020 | 06:29 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 7/24/2020 | 06:08 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 7/23/2020 | 12:45 | GlobeNewswire Inc. | Immuron Limited Announces Closing of $20.0 Million.. |
| 7/23/2020 | 08:14 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 7/23/2020 | 06:03 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 7/21/2020 | 09:11 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 7/21/2020 | 08:45 | GlobeNewswire Inc. | Immuron Announces $20.0 Million Registered Direct Offering |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IMRN Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |
